LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus
Phase 4
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- Registration Number
- NCT00349986
- Lead Sponsor
- Sanofi
- Brief Summary
The rationale of the study is to determine:
* the first dose and the titration of basal insulin
* the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 4
Inclusion Criteria
- Type 2 Diabetes Mellitus
- Insufficient combined oral antidiabetic treatment (biguanide + sulfonylurea)
- BMI >25 kg/m2 , <30 kg/m2
- HbA1c value >7.0%, <9.0% within one month
Read More
Exclusion Criteria
- Type 1 Diabetes Mellitus
- Known malignancy
- Drug or alcohol abuse
- Severe liver disease
- Renal failure (se Creatinine > 150 micro mol/l)
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HgbA1c measurement
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Sanofi-Aventis
🇭🇺Budapest, Hungary